Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

M6620 Plus Standard Treatment in Oesophageal and Other Cancer

Phase 1

Completed

Conditions: Oesophageal Adenocarcinoma
Squamous Cell Carcinoma
Solid Tumor

Interventions: Drug: M6620
Drug: Cisplatin
Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2018-08-22

Last Posted Date: 2024-07-18

Lead Sponsor: University of Oxford

Target Recruit Count: 36

Registration Number: NCT03641547

Locations: 🇬🇧
St James's University Hospital, Leeds, United Kingdom
🇬🇧
The Christie, Manchester, United Kingdom
🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom

and more 2 locations

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Phase 3

Completed

Conditions: Cervical Cancer

Interventions: Biological: Pembrolizumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo to pembrolizumab
Biological: Bevacizumab

First Posted Date: 2018-08-17

Last Posted Date: 2024-06-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 617

Registration Number: NCT03635567

Locations: 🇦🇺
Monash Health-Monash Medical Centre ( Site 1519), Clayton, Australia
🇺🇸
Seattle Cancer Care Alliance ( Site 1777), Seattle, Washington, United States
🇯🇵
Shizuoka Cancer Center Hospital and Research Institute ( Site 1703), Sunto-gun, Shizuoka, Japan

and more 146 locations

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: canakinumab
Drug: canakinumab-matching placebo
Drug: pembrolizumab
Drug: carboplatin
Drug: cisplatin
Drug: pemetrexed
Drug: paclitaxel
Drug: nab-paclitaxel

First Posted Date: 2018-08-15

Last Posted Date: 2024-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 673

Registration Number: NCT03631199

Locations: 🇺🇸
Pacific Shores Medical Group ., Long Beach, California, United States
🇺🇸
USC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States
🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States

and more 2 locations

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Phase 3

Completed

Conditions: Squamous NSCLC

Interventions: Drug: Sintilimab
Drug: Gemcitabine
Drug: Placebo
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2018-08-14

Last Posted Date: 2023-02-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 357

Registration Number: NCT03629925

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Phase 3

Conditions: Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin T-cell Lymphoma
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Etoposide (VP-16)
Device: Ifosfamide
Drug: Dexamethasone
Drug: L-asparaginase

First Posted Date: 2018-08-09

Last Posted Date: 2018-08-14

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 68

Registration Number: NCT03623087

Locations: 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

Phase 2

Active, not recruiting

Conditions: HPV Related Oropharyngeal Squamous Cell Carcinoma

Interventions: Drug: Cisplatin
Radiation: Intensity modulated radiation therapy
Radiation: Intensity modulated proton therapy
Procedure: Surgery
Other: FACT-H&N
Other: MD Anderson Dysphagia Inventory
Other: University of Michigan Xerostomia Index
Other: Scale of Subjective Total Taste Acuity
Other: Neck Dissection Impairment Index

First Posted Date: 2018-08-08

Last Posted Date: 2024-08-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 63

Registration Number: NCT03621696

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: Sintilimab
Drug: Gemcitabine
Drug: Cisplatin
Radiation: intensity-modulated radiotherapy

First Posted Date: 2018-08-08

Last Posted Date: 2018-10-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 40

Registration Number: NCT03619824

Locations: 🇨🇳
SUN YAT-SEN UNIVERSITY cANCER CENTER, Guangzhou, Guangdong, China

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2

Completed

Conditions: Stage II Ureter Cancer AJCC v8
Stage II Urethral Cancer AJCC v8
Stage III Renal Pelvis Cancer AJCC v8
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall
Stage II Bladder Cancer AJCC v8
Stage III Ureter Cancer AJCC v8
Stage III Urethral Cancer AJCC v8
Urethral Urothelial Carcinoma
Stage II Renal Pelvis Cancer AJCC v8
Stage III Bladder Cancer AJCC v8

Interventions: Drug: Avelumab
Drug: Cisplatin
Drug: Fluorouracil
Drug: Mitomycin
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2018-08-07

Last Posted Date: 2023-01-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT03617913

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Phase 3

Active, not recruiting

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Placebo
Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-FU
Drug: Oxaliplatin
Drug: Capecitabine
Drug: S-1
Biological: Trastuzumab

First Posted Date: 2018-08-03

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 738

Registration Number: NCT03615326

Locations: 🇪🇸
Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, Spain
🇺🇸
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, United States
🇺🇸
University of Rochester ( Site 0041), Rochester, New York, United States

and more 189 locations

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Apatinib mesylate tablet
Radiation: Intensity-modulated radiation therapy (IMRT)
Drug: Cisplatin

First Posted Date: 2018-08-02

Last Posted Date: 2018-08-02

Lead Sponsor: Wei Jiang

Target Recruit Count: 240

Registration Number: NCT03612219

Locations: 🇨🇳
Guangxi Naxishan Hospital, Guilin, Guangxi, China
🇨🇳
People's Hospital of Lingshan, Linshan, Guangxi, China
🇨🇳
Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy